Decode Shares Tumble 14 Percent After Company Halts Heart Drug Study

Oct 06, 2006

NEW YORK (GenomeWeb News) — Shares in Decode Genetics were down 14.19 percent, or $.82, at $5.02 in mid-afternoon trading after the company said it was forced to halt the study of a heart drug.

Decode said it suspended the Pjhase III trial of its heart attack drug DG031 after discovering that tablets appear to dissolve more slowly over time than had been originally believed.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Breaking News

The Scan

Faster Profiles

The Washington Post reports on a Federal Bureau of Investigation plan to place rapid DNA analyzers at booking stations around the country.

Standards Needed

In an editorial, officials from scientific societies in the US and China call for the international community to develop criteria and standards for human germline editing.

Conflict Search

The US National Institutes of Health is to review studies that have received private support for conflicts of interest, according to the New York Times.

This Week in Science

In Science this week: the PsychENCODE Consortium reports on the molecular mechanisms of neuropsychiatric disorders, and more.

Main menu